The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF for recipients with previous transplants. In this study, we analyzed patients who received previous transplants, treated with the above immunosuppressive regimen. Group A consisted of four patients with previous liver transplants, group B consisted of 16 recipients with previous kidney transplants and group C consisted of three patients with previous simultaneous pancreas-kidney transplants. All patients underwent cadaveric kidney transplants except one patient in group B, who underwent a pancreas transplant. At 12 months, patient and graft survival for all groups was 100 and 100%, respectively. Acute rejection rate was 0% for group A, 12.5% for group B, and 0% for group C. Daclizumab induction therapy is effective for patients with previous transplants and does not appear to increase the risk of acute rejection.

Original languageEnglish (US)
Pages (from-to)428-432
Number of pages5
JournalClinical Transplantation
Volume17
Issue number5
DOIs
StatePublished - Oct 1 2003

Keywords

  • Acute rejection
  • Induction therapy
  • Mycophenolate mofetil
  • Previous transplants
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants'. Together they form a unique fingerprint.

  • Cite this